A clinical decision framework for redox-adapted, EMT-high cancers: From ferroptosis resistance to precision...

Therapeutic resistance in advanced solid tumors increasingly reflects the emergence of adaptive tumor states rather than the absence of actionable molecular targets. Among these, redox adaptation represents a clinically decisive program that integrates ferroptosis resistance, epithelial-mesenchymal transition (EMT)-driven plasticity, metabolic rewiring, immune evasion, and extracellular vesicle-mediated communication. Here, we propose a state-based redox-EMT framework that explicitly translates these adaptive programs into clinical decision rules for patient stratification, therapeutic sequencing, and trial design. We synthesize mechanistic and translational evidence demonstrating that NRF2-centered antioxidant buffering and multilayered ferroptosis defense constitute an independent resistance axis that frequently supersedes oncogene dependency, particularly in metabolically compromised hosts such as patients with type 2 diabetes-associated pancreatic ductal adenocarcinoma (PDAC). Building on this concept, we delineate discrete redox-EMT tumor states, ranging from redox-low, EMT-restricted phenotypes to terminal redox-locked ecosystems characterized by ferroptosis resistance, stromal insulation, and immune exclusion. Importantly, we translate these states into actionable clinical decision rules, linking ferroptosis defense markers (e.g., GPX4, SLC7A11, FSP1), NRF2 activity, EMT status, and host metabolic context to rational selection and sequencing of cytotoxic therapy, targeted agents, redox modulation, and immunotherapy. We further outline a biomarker-guided stratification strategy integrating tissue-based and liquid biopsy readouts, including circulating tumor DNA, exosomal PD-L1, and redox-responsive microRNAs, to enable dynamic monitoring of tumor redox states during treatment. By reframing redox adaptation as a measurable, stratifiable, and targetable tumor state, this work provides a decision-oriented roadmap for state-aware precision oncology. Collectively, our framework supports a shift from mutation-centric treatment escalation toward clinical algorithms that anticipate and intercept redox-adapted therapeutic resistance, with direct implications for biomarker-enriched trials and adaptive treatment strategies in PDAC and beyond.